Ab­b­Vie touts new da­ta for Hu­mi­ra suc­ces­sor; Gilead inks dis­cov­ery deal

6 years ago
News Briefing

Turns out, Rudy Tanzi did­n't see much of a sto­ry about a hid­den link be­tween En­brel and Alzheimer's ei­ther

6 years ago
People
Bioregnum

Gene ther­a­pies seize the top of the list of the most ex­pen­sive drugs on the plan­et — and that trend has just be­gun

6 years ago
Pharma
Cell/Gene Tx

Adding mar­quee in­vestors, Black­Thorn bags $76M to back an AI-dri­ven strat­e­gy for pre­ci­sion neu­ro med­i­cine

6 years ago
Financing
Startups

J&J gains an en­thu­si­as­tic en­dorse­ment from Pres­i­dent Don­ald Trump for their big new drug Spra­va­to

6 years ago
People
Pharma

Savara shares are crushed as PhI­II tri­al flunks pri­ma­ry, key sec­on­daries — but they can’t stop be­liev­ing

6 years ago
R&D

As an­oth­er an­tibi­otics biotech sinks in­to a cri­sis, warn­ings of a sec­tor ‘col­lapse’

6 years ago
R&D

Fol­low­ing CAR-T pi­o­neer­s' foot­steps, Tes­sa launch­es Chi­na JV in $120M deal

6 years ago
Financing
China

An in­censed Cat­a­lyst Phar­ma sues the FDA, ac­cus­ing agency of bow­ing to po­lit­i­cal pres­sure and break­ing fed­er­al law

6 years ago
Pharma
FDA+

Tech con­glom­er­ate buys Me­di­da­ta for $5.7B; Alexan­dria teams up with Co­lum­bia for sec­ond Launch­Labs; So­bi all in on ...

6 years ago
News Briefing

Or­biMed-backed Pre­lude Ther­a­peu­tics rais­es $60M to tack­le re­sis­tance to can­cer treat­ments

6 years ago
Financing
Startups

Plagued by de­lays, As­traZeneca HQ costs soar to £750M as it edges to­ward 2020 com­ple­tion

6 years ago
Pharma

Fresh analy­sis spot­lights car­dio ben­e­fit of J&J's In­vokana in di­a­betes pa­tients with­out his­to­ry of CV dis­ease

6 years ago
Pharma

Sil­i­con Val­ley's most an­tic­i­pat­ed slide deck just dropped. What does it mean for bio­phar­ma's dig­i­tal teams?

6 years ago
Bioregnum
Pharma

Bain’s biotech team has cre­at­ed a $1B-plus fund — with an eye to more Big Phar­ma spin­outs

6 years ago
Financing

Syn­log­ic, Gink­go ex­pand mi­cro­bial dis­cov­ery pact, throw­ing $80M in­vest­ment in­to the mix

6 years ago
R&D

ADC Ther­a­peu­tics beefs up mon­ster $200M round with fresh $76M haul

6 years ago
Financing

Roche cat­a­pults Thomas Schi­neck­er to chief of di­ag­nos­tics unit

6 years ago
People

Nas­daq delists In­sys af­ter bank­rupt­cy fil­ing; Chi­na's Zai Lab li­cens­es sol­id tu­mor drug from De­ci­phera

6 years ago
News Briefing

Search­ing for the next block­buster to fol­low Darza­lex, J&J finds a $150M an­ti-CD38 drug from part­ner Gen­mab

6 years ago
R&D

Mer­ck grows Keytru­da in­di­ca­tions with head and neck can­cer ap­proval

6 years ago
Pharma

NASH con­tender CymaBay runs in­to trou­ble as mid-stage da­ta dis­ap­point

6 years ago
R&D

Russ­ian sci­en­tist plans to one-up Jiankui He in cre­at­ing his own CRISPR ba­bies — Na­ture

6 years ago
Discovery

With a sub­stan­tial dis­count to Cat­a­lyst's Fir­dapse, is Ja­cobus poised to win physi­cian, pay­er sup­port for off-la­bel ...

6 years ago
Pharma
First page Previous page 926927928929930931932 Next page Last page
A service from the Financial Times